Camurus AB (CAMRF) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cam2029 | Polycystic Liver Disease | phase2AndPhase3 | Active Not Recruiting | A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD | Mar 07, 2022 | ― |
| Cam2029, Octreotide Lar, Lanreotide Atg | Gastro-Enteropancreatic Neuroendocrine Tumor | Phase III | Active Not Recruiting | A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET | Sep 09, 2021 | ― |
| Cam2029 | Acromegaly | Phase III | Completed | A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly | Oct 11, 2019 | ― |
| Cam2029 | Acromegaly | Phase III | Completed | A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly | Aug 29, 2019 | ― |
| Buprenorphine | Chronic Pain, Chronic Lower Back Pain | Phase III | Completed | Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain | Oct 07, 2016 | ― |
| Octreotide Fluidcrystal Injection Depot | Neuroendocrine Tumors, Acromegaly | Phase II | Completed | Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) | Nov 17, 2014 | ― |
| Leuprolide Acetate Fluidcrystal Injection Depot, Leuprolide Acetate | Prostate Cancer | Phase II | Completed | Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer | Aug 05, 2014 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cam2029 | phase2AndPhase3 | Polycystic Liver Disease | Active Not Recruiting | A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD | Mar 07, 2022 | ― |
| Cam2029, Octreotide Lar, Lanreotide Atg | Phase III | Gastro-Enteropancreatic Neuroendocrine Tumor | Active Not Recruiting | A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET | Sep 09, 2021 | ― |
| Cam2029 | Phase III | Acromegaly | Completed | A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly | Oct 11, 2019 | ― |
| Cam2029 | Phase III | Acromegaly | Completed | A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly | Aug 29, 2019 | ― |
| Buprenorphine | Phase III | Chronic Pain, Chronic Lower Back Pain | Completed | Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain | Oct 07, 2016 | ― |
| Octreotide Fluidcrystal Injection Depot | Phase II | Neuroendocrine Tumors, Acromegaly | Completed | Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) | Nov 17, 2014 | ― |
| Leuprolide Acetate Fluidcrystal Injection Depot, Leuprolide Acetate | Phase II | Prostate Cancer | Completed | Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer | Aug 05, 2014 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Camurus AB (CAMRF) have in its pipeline
Camurus AB CAMRF is currently developing the following drugs: Cam2029, Cam2029, Octreotide Lar, Lanreotide Atg, Buprenorphine, Octreotide Fluidcrystal Injection Depot, Leuprolide Acetate Fluidcrystal Injection Depot, Leuprolide Acetate. These drug candidates are in various stages of clinical development as the company works toward FDA approval.